INGENASA is a Biotech SME dedicated to research, development and marketing of products designed to the diagnosis and prevention of infectious diseases, especially those affecting the Animal Health sector. The company based in Madrid has 43 employees, mostly women, and has 30 years’ experience in the development of recombinant proteins and monoclonal antibodies which have been used for the development of diagnostic test for many veterinary diseases, which are currently commercialized. Also, INGENASA is active in areas of prevention of animal diseases and has participated in several European project funded by the EU in the BRIDGE, BIOTECH, FAIR, FP5, FP6 and FP7 programmes dedicated to: “Development of second generation vaccines against parvoviruses”, “the use of recombinant baculovirus-expressed particles as delivery systems”, “Edible vaccines”, “Metapneumovirus molecular and clinical studies for disease control”, “Optimised delivery systems for vaccines targeted to dendritic cells” and “Immuno response to viral respiratory infections and vaccination in the elderly”. Based on this research INGENASA has registered more than 50 patents and has designed a new system for the production of empty viral capsids for different parvo- and calicivirus The research activities (50% of the total sales) are partially funded by national grants from the Spanish Governmental Agencies and from European Union Framework Programmes. The facilities of INGENASA are located on two floors from adjoining buildings, with a total area of 2000 m2. All the activities performed in these facilities have the specific permission required. The company is ISO 9001 and ISO 14001certified.